Brown Advisory Securities’s Regulus Therapeutics RGLS Stock Holding History

Brown Advisory Securities’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-125	Closed	-$3K	–	423
2018 Q3	$3K	Hold	125	–	–	﹤0.01%	425
2018 Q2	$10K	Buy	+125	New	+$10.3K	﹤0.01%	418

Other funds holding RGLS

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Brown Advisory Securities's RGLS Position: Q4 2018 in Review

Brown Advisory Securities sold out of Regulus Therapeutics (RGLS) in Q4 2018, closing a stake of 125 shares — an estimated $3K sold.

Brown Advisory Securities first reported a position in RGLS in Q2 2018 and held it in 2 quarters. The position peaked at $10K in Q2 2018. 27 funds tracked by Wall St. Rank hold RGLS as of Q4 2018.

Brown Advisory Securities reported no remaining Regulus Therapeutics position as of Q4 2018 after selling out during the quarter.
Brown Advisory Securities sold 125 Regulus Therapeutics shares in Q4 2018, an estimated $3K.
Brown Advisory Securities first reported a position in Regulus Therapeutics in Q2 2018 and held it in 2 quarters.
Brown Advisory Securities's Regulus Therapeutics position peaked at $10K in Q2 2018.
27 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2018.

Based on Brown Advisory Securities's 13F filing for Q4 2018, filed 13 Feb 2019.